Atlas Trials

Karyopharm Therapeutics Inc

37 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Karyopharm Therapeutics Inc

RecordFirmDate
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (NCT05980806)Karyopharm Therapeutics Inc2024-04-22
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (NCT05611931)Karyopharm Therapeutics Inc2023-04-18
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations (NCT04854434)Karyopharm Therapeutics Inc2021-06-29
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma (NCT04768881)Karyopharm Therapeutics Inc2021-05-12
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis (NCT04562870)Karyopharm Therapeutics Inc2021-03-17
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis (NCT04562389)Karyopharm Therapeutics Inc2021-03-11
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) (NCT04607772)Karyopharm Therapeutics Inc2020-11-18
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT04442022)Karyopharm Therapeutics Inc2020-09-03
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. (NCT04414475)Karyopharm Therapeutics Inc2020-07-01
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma (NCT04421378)Karyopharm Therapeutics Inc2020-06-08
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 (NCT04355676)Karyopharm Therapeutics Inc2020-04-30
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (NCT04349098)Karyopharm Therapeutics Inc2020-04-17
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] (NCT03555422)Karyopharm Therapeutics Inc2018-01-05

Track Karyopharm Therapeutics Inc automatically

Every clearance here is in the API, with alerts when new ones post.